Mechanisms and Biosensors of GTPases
Daniel Abankwa, PhD
Affiliated Group Leader
daniel.abankwa [at] btk.fi
Adjunct Professor at Åbo Akademi University
The number of cancer caused deaths in the world is expected to rise from about 9M in 2015 to 15M in the following 20 years. Novel therapeutic approaches against cancer are therefore urgently needed.
We are developing novel targeted drugs, which would be administered in a personalized manner, depending on gene expression, mutation or other diagnostic parameters from the patient.
We focus on specifically inhibiting the aberrant activity of one of the cancer associated Ras isoforms encoded by HRAS, NRAS or KRAS genes.
Our research aims here are:
- Drug Development– to develop novel drugs that block RAS signalling in cancer.
- Target Nomination– to understand which components of RAS interaction network in particular on the membrane (nanocluster) could be targeted with drugs to block RAS-dependent stemness signalling.
- molecular cell biology (2D proliferation, 3D sphere cultures, inducible lentiviral vectors, knock-down and out etc.)
- biochemistry (assay development, protein interaction, structure etc.)
- quantitative fluorescence methods and confocal imaging (FRET, FRAP etc.)
Additional information on our activities can be found here: https://erasecancer.wordpress.com
Group Members active in Turku:
Christina Oetken-Lindholm, PhD
Matias Knuuttila, PhD
Hanna Parkkola, PhD
Farid A. Siddiqui, MSc